Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30783202 | 0.93 | PROKR1 (0.52) | HSD11B1GPR119HPGDSUSP30MAPT | |
| SCHEMBL3436365 | 0.92 | GPR119 (0.58) | GPR119HPGDSNAMPTTRPV1KDM4E | |
| SCHEMBL17679904 | 0.89 | KDM4E (0.49) | HSD11B1GPR119USP30NAMPTKDM4E | |
| SCHEMBL28334298 | 0.87 | GPR119 (0.50) | GPR119HPGDSPDE4BUSP30NAMPT | |
| SCHEMBL21352382 | 0.87 | GPR119 (0.50) | GPR119HPGDSPDE4BUSP30NAMPT | |
| SCHEMBL2078377 | 0.87 | GPR119 (0.50) | GPR119HPGDSPDE4BUSP30NAMPT | |
| SCHEMBL27393884 | 0.86 | GPR119 (0.53) | GPR119PDE4BKDM4EMAPTTHRB | |
| SCHEMBL25044033 | 0.86 | MEN1 (0.59) | GPR119HPGDSPDE4BTP53 | |
| SCHEMBL4939245 | 0.86 | GPR119 (0.52) | GPR119HPGDSPDE4BUSP30NAMPT | |
| SCHEMBL19404952 | 0.85 | GPR119 (0.53) | GPR119HPGDSPDE4BUSP30NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HSD11B1 3972/4885GPR119 77/4885HPGDS 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.